Christopher C. Nessel
About
Christopher C. Nessel is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Epidemiology.
According to data from OpenAlex, Christopher C. Nessel has authored 75 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Cardiology and Cardiovascular Medicine, 32 papers in Internal Medicine and 10 papers in Epidemiology. Recurrent topics in Christopher C. Nessel's work include Atrial Fibrillation Management and Outcomes (69 papers), Venous Thromboembolism Diagnosis and Management (32 papers) and Cardiac Arrhythmias and Treatments (27 papers). Christopher C. Nessel is often cited by papers focused on Atrial Fibrillation Management and Outcomes (69 papers), Venous Thromboembolism Diagnosis and Management (32 papers) and Cardiac Arrhythmias and Treatments (27 papers). Christopher C. Nessel collaborates with scholars based in United States, United Kingdom and Germany. Christopher C. Nessel's co-authors include Kenneth W. Mahaffey, Manesh R. Patel, Keith A.A. Fox, Daniel E. Singer, Graeme J. Hankey, Jonathan P. Piccini, Richard C. Becker, Jonathan L. Halperin, Robert M. Califf and Günter Breithardt and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Christopher C. Nessel
75 papers receiving 11.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Christopher C. Nessel United States | 34 | 10.8k | 5.4k | 1.7k | 610 | 565 | 75 | 11.5k | ||
| Ellison Themeles Canada | 11 | 9.7k 0.9× | 4.0k 0.7× | 1.5k 0.9× | 678 1.1× | 583 1.0× | 15 | 10.5k | ||
| Jeanne Varrone United States | 4 | 8.4k 0.8× | 4.0k 0.7× | 1.4k 0.8× | 543 0.9× | 576 1.0× | 7 | 9.1k | ||
| Amit Parekh United States | 10 | 8.1k 0.8× | 3.8k 0.7× | 1.3k 0.8× | 559 0.9× | 538 1.0× | 28 | 8.9k | ||
| Marco Alings Netherlands | 31 | 12.8k 1.2× | 5.6k 1.0× | 2.0k 1.2× | 985 1.6× | 790 1.4× | 87 | 14.0k | ||
| Susan Wang United States | 8 | 8.2k 0.8× | 3.9k 0.7× | 1.3k 0.8× | 557 0.9× | 552 1.0× | 12 | 9.3k | ||
| Jun Zhu China | 28 | 9.9k 0.9× | 4.0k 0.7× | 1.7k 1.0× | 1.0k 1.7× | 616 1.1× | 133 | 11.3k | ||
| John F. Paolini United States | 32 | 8.1k 0.7× | 3.8k 0.7× | 1.6k 0.9× | 1.3k 2.2× | 539 1.0× | 90 | 10.5k | ||
| Jyotsna Garg United States | 14 | 7.0k 0.7× | 3.2k 0.6× | 1.8k 1.1× | 1.2k 2.0× | 423 0.7× | 23 | 10.0k | ||
| Werner Hacke Germany | 41 | 12.9k 1.2× | 6.0k 1.1× | 2.6k 1.6× | 1.0k 1.7× | 687 1.2× | 117 | 14.3k | ||
| Ron Pisters Netherlands | 20 | 9.2k 0.9× | 2.9k 0.5× | 1.7k 1.0× | 584 1.0× | 656 1.2× | 59 | 10.0k |
Countries citing papers authored by Christopher C. Nessel
Since
Specialization
Citations
This map shows the geographic impact of Christopher C. Nessel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher C. Nessel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher C. Nessel more than expected).
Fields of papers citing papers by Christopher C. Nessel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Christopher C. Nessel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher C. Nessel. The network helps show where Christopher C. Nessel may publish in the future.
Co-authorship network of co-authors of Christopher C. Nessel
This figure shows the co-authorship network connecting the top 25 collaborators of Christopher C. Nessel. A scholar is included among the top collaborators of Christopher C. Nessel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher C. Nessel. Christopher C. Nessel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Harrington, Josephine, Anne S. Hellkamp, Kenneth W. Mahaffey, et al.. (2024). Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal of the American Heart Association. 13(11). e028951–e028951.
2.
Greenberg, Barry, James D. Neaton, Stefan D. Anker, et al.. (2019). Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. JAMA Cardiology. 4(6). 515–515.
3.
Greenberg, Barry, Stefan D. Anker, William M. Byra, et al.. (2018). Effects of Rivaroxaban on Thrombotic Events in Heart Failure Patients With Coronary Disease and Sinus Rhythm. Circulation. 138(25).
4.
Chen, Sean T., Anne S. Hellkamp, Richard C. Becker, et al.. (2018). Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. American Heart Journal. 200. 102–109.
5.
Yuan, Žhong, Erica A. Voss, Frank DeFalco, et al.. (2017). Risk Prediction for Ischemic Stroke and Transient Ischemic Attack in Patients Without Atrial Fibrillation: A Retrospective Cohort Study. Journal of Stroke and Cerebrovascular Diseases. 26(8). 1721–1731.
6.
Washam, Jeffrey B., Susanna R. Stevens, Yuliya Lokhnygina, et al.. (2015). Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). The Lancet. 385(9985). 2363–2370.
7.
Steinberg, Benjamin A., Anne S. Hellkamp, Yuliya Lokhnygina, et al.. (2014). Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm. 11(6). 925–932.
8.
Cyr, Derek D., Yuliya Lokhnygina, Richard C. Becker, et al.. (2014). OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL. Journal of the American College of Cardiology. 63(12). A371–A371.
9.
Breithardt, Günter, Helmut Baumgartner, Scott D. Berkowitz, et al.. (2014). Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European Heart Journal. 35(47). 3377–3385.
10.
Steinberg, Benjamin A., Anne S. Hellkamp, Yuliya Lokhnygina, et al.. (2014). Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal. 36(5). 288–296.
11.
Diepen, Sean van, Anne S. Hellkamp, Manesh R. Patel, et al.. (2013). Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation Heart Failure. 6(4). 740–747.
12.
Piccini, Jonathan P., Susanna R. Stevens, Yuliya Lokhnygina, et al.. (2013). Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. Journal of the American College of Cardiology. 61(19). 1998–2006.
13.
Levitan, Bennett, Žhong Yuan, Juan Marcos González, et al.. (2013). Patient And Physician Preferences In The United States For Benefits And Risks Of Anticoagulant Use In Atrial Fibrillation – Results From A Conjoint-Analysis Study. Value in Health. 16(3). A11–A11.
14.
Piccini, Jonathan P., Susanna R. Stevens, Yuchiao Chang, et al.. (2012). Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation. 127(2). 224–232.
15.
Piccini, Jonathan P., Susanna R. Stevens, Yuliya Lokhnygina, et al.. (2012). Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial. Circulation. 126(suppl_21).
16.
Halperin, Jonathan L., Zachary T. Bloomgarden, Anne S. Hellkamp, et al.. (2012). Abstract 15544: Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial. Circulation. 126.
17.
Halperin, Jonathan L., Zachary T. Bloomgarden, Anne S. Hellkamp, et al.. (2012). Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial. UWA Profiles and Research Repository (University of Western Australia). 126(21).
18.
Patel, Manesh R., Kenneth W. Mahaffey, Jyotsna Garg, et al.. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 365(10). 883–891.
19.
Mahaffey, Kenneth W., Harvey D. White, Christopher C. Nessel, et al.. (2011). Abstract 13482: Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial. Circulation. 124.
20.
Petersen, John L., Kenneth W. Mahaffey, Richard C. Becker, et al.. (2004). Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. American Heart Journal. 148(2). 269–276.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ellison Themeles Breakdown of academic impact, for papers by Jeanne Varrone Breakdown of academic impact, for papers by Amit Parekh Breakdown of academic impact, for papers by Marco Alings Breakdown of academic impact, for papers by Susan Wang Breakdown of academic impact, for papers by Jun Zhu Breakdown of academic impact, for papers by John F. Paolini Breakdown of academic impact, for papers by Jyotsna Garg Breakdown of academic impact, for papers by Werner Hacke Breakdown of academic impact, for papers by Ron Pisters